+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Mild Cognitive Impairment - Pipeline Review, H2 2019

  • ID: 4866550
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 116 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Biogen Inc
  • CuraSen Therapeutics Inc
  • IntelGenx Corp
  • Neuron Biopharma SA
  • Partner Therapeutics Inc
  • MORE
Mild Cognitive Impairment - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2019, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape.

Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. Symptoms include depression, irritability and aggression, anxiety and apathy. Risk factors include diabetes, high blood pressure, and depression, smoking and elevated cholesterol.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Mild Cognitive Impairment (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 3, 1, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Mild Cognitive Impairment (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mild Cognitive Impairment (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mild Cognitive Impairment (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Biogen Inc
  • CuraSen Therapeutics Inc
  • IntelGenx Corp
  • Neuron Biopharma SA
  • Partner Therapeutics Inc
  • MORE
Introduction
Report Coverage
Mild Cognitive Impairment - Overview
Mild Cognitive Impairment - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Mild Cognitive Impairment - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Mild Cognitive Impairment - Companies Involved in Therapeutics Development
AbbVie Inc
Addex Therapeutics Ltd
AgeneBio Inc
Avraham Pharmaceuticals Ltd
Biogen Inc
Cerebrum Therapeutics Inc
CereSpir Inc
CuraSen Therapeutics Inc
Eli Lilly and Co
Fujifilm Toyama Chemical Co Ltd
Grespo AB
ImmunoChem Therapeutics LLC
IntelGenx Corp
Merck & Co Inc
NeurAegis Inc
Neuron Biopharma SA
NLS Pharma Group
Octapharma AG
Partner Therapeutics Inc
Pfizer Inc
ProNeurogen Inc
Protekt Therapeutics Ltd
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Therapix Biosciences Ltd
Mild Cognitive Impairment - Drug Profiles
ABBV-8E12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bosutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexanolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CST-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DAOI-B - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit Calpain 2 for Mild Cognitive Impairment - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gosuranemab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRE-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itanapraced - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladostigil tartrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levetiracetam ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levofacetoperane - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4334 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
montelukast sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MW-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPS-0158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPS-0163 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0037 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NST-0078 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Agonize Insulin Receptor for Mild Cognitive Impairment and Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNA-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sargramostim - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Mild Cognitive Impairment - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit EIF2AK2 for Mild Cognitive Impairment - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GABRA5 for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-817MA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THX-130 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zagotenemab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Mild Cognitive Impairment - Dormant Projects
Mild Cognitive Impairment - Discontinued Products
Mild Cognitive Impairment - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Mild Cognitive Impairment, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Universities/Institutes, H2 2019
Table 8: Number of Products by Stage and Target, H2 2019
Table 9: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 10: Number of Products by Stage and Mechanism of Action, H2 2019
Table 11: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 12: Number of Products by Stage and Route of Administration, H2 2019
Table 13: Number of Products by Stage and Molecule Type, H2 2019
Table 14: Mild Cognitive Impairment - Pipeline by AbbVie Inc, H2 2019
Table 15: Mild Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H2 2019
Table 16: Mild Cognitive Impairment - Pipeline by AgeneBio Inc, H2 2019
Table 17: Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd, H2 2019
Table 18: Mild Cognitive Impairment - Pipeline by Biogen Inc, H2 2019
Table 19: Mild Cognitive Impairment - Pipeline by Cerebrum Therapeutics Inc, H2 2019
Table 20: Mild Cognitive Impairment - Pipeline by CereSpir Inc, H2 2019
Table 21: Mild Cognitive Impairment - Pipeline by CuraSen Therapeutics Inc, H2 2019
Table 22: Mild Cognitive Impairment - Pipeline by Eli Lilly and Co, H2 2019
Table 23: Mild Cognitive Impairment - Pipeline by Fujifilm Toyama Chemical Co Ltd, H2 2019
Table 24: Mild Cognitive Impairment - Pipeline by Grespo AB, H2 2019
Table 25: Mild Cognitive Impairment - Pipeline by ImmunoChem Therapeutics LLC, H2 2019
Table 26: Mild Cognitive Impairment - Pipeline by IntelGenx Corp, H2 2019
Table 27: Mild Cognitive Impairment - Pipeline by Merck & Co Inc, H2 2019
Table 28: Mild Cognitive Impairment - Pipeline by NeurAegis Inc, H2 2019
Table 29: Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2019
Table 30: Mild Cognitive Impairment - Pipeline by NLS Pharma Group, H2 2019
Table 31: Mild Cognitive Impairment - Pipeline by Octapharma AG, H2 2019
Table 32: Mild Cognitive Impairment - Pipeline by Partner Therapeutics Inc, H2 2019
Table 33: Mild Cognitive Impairment - Pipeline by Pfizer Inc, H2 2019
Table 34: Mild Cognitive Impairment - Pipeline by ProNeurogen Inc, H2 2019
Table 35: Mild Cognitive Impairment - Pipeline by Protekt Therapeutics Ltd, H2 2019
Table 36: Mild Cognitive Impairment - Pipeline by Sage Therapeutics Inc, H2 2019
Table 37: Mild Cognitive Impairment - Pipeline by SBI Pharmaceuticals Co Ltd, H2 2019
Table 38: Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H2 2019
Table 39: Mild Cognitive Impairment - Dormant Projects, H2 2019
Table 40: Mild Cognitive Impairment - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 41: Mild Cognitive Impairment - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Mild Cognitive Impairment, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • AgeneBio Inc
  • Avraham Pharmaceuticals Ltd
  • Biogen Inc
  • Cerebrum Therapeutics Inc
  • CereSpir Inc
  • CuraSen Therapeutics Inc
  • Eli Lilly and Co
  • Fujifilm Toyama Chemical Co Ltd
  • Grespo AB
  • ImmunoChem Therapeutics LLC
  • IntelGenx Corp
  • Merck & Co Inc
  • NeurAegis Inc
  • Neuron Biopharma SA
  • NLS Pharma Group
  • Octapharma AG
  • Partner Therapeutics Inc
  • Pfizer Inc
  • ProNeurogen Inc
  • Protekt Therapeutics Ltd
  • Sage Therapeutics Inc
  • SBI Pharmaceuticals Co Ltd
  • Therapix Biosciences Ltd
Note: Product cover images may vary from those shown
Adroll
adroll